Press Releases Genmab A/S

Equities

Market Closed - Nasdaq Copenhagen Other stock markets 15:59:33 03/05/2024 BST			5-day change	1st Jan Change
2,061 ^DKK	+5.91%		+5.45%	-4.36%

05-03	GENMAB : A good start to 2024; guidance unchanged
05-03	Genmab Posts Q1 Net Profit Surge; Revenue Jumps	MT

Genmab A/S : Investor Presentation - May 2024	05-02	PU
Genmab A/S : Interim Report for the First Quarter of 2024	05-02	PU
Genmab A/S : First Quarter 2024 Financial Results Presentation	05-02	PU
Genmab Announces Financial Results for the First Quarter of 2024	05-02	GL
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer	04-29	GL
Transactions in Connection with Share Buy-back Program Genmab	04-29	GL
Transactions in Connection with Share Buy-back Program Genmab	04-22	GL
Transactions in Connection with Share Buy-back Program Genmab	04-22	AQ
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2024	04-16	GL
Transactions in Connection with Share Buy-back Program Genmab	04-15	GL
Transactions in Connection with Share Buy-back Program	04-08	GL
ADC oncology acquisition to address solid tumours	04-03	AQ
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio	04-03	BU
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio	04-03	GL
Transactions in Connection with Share Buy-back Program	04-02	GL
Transactions in Connection with Share Buy-back Program	03-25	GL
Genmab A/S : has published its Articles of Association	03-21	PU
Completion of share buy-back program	03-18	GL
Genmab Announces Initiation of Share Buy-Back Program	03-15	GL
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons	03-13	GL

No results for this search

GENMAB : A good start to 2024; guidance unchanged

May 03, 2024 at 06:08 pm